50 Results

People

  1. Aghajanian
    Aghajanian
  2. Gerecitano
    Gerecitano
  3. Moskowitz
    Moskowitz
  4. O'connor
    O'connor
  5. Prochaska
    Prochaska
  6. Zelenetz
    Zelenetz
  7. Gonen
    Gonen
  8. Spriggs
    Spriggs
  9. Baron
    Baron
  10. Dumitrescu
    Dumitrescu

Groups

  1. Department of Medicine (29)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (14)
  4. Solid Tumor Oncology Division (13)
  5. Biostatistics Service (9)
  6. Epidemiology and Biostatistics (9)
  7. Nursing (8)
  8. Center for Pancreatic Cancer Research (6)
  9. GDMT, Medicine (5)
  10. Genitourinary Oncology Service (5)
  1. "pyrazines"
Formats
  1. Journal Article (49)
  2. Research Letter (1)
Groups
  1. Department of Medicine (29)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (14)
  4. Solid Tumor Oncology Division (13)
  5. Biostatistics Service (9)
  6. Epidemiology and Biostatistics (9)

More Groups

People
  1. Owen O'connor (9)
  2. Andrew Zelenetz (5)
  3. Carol Aghajanian (5)
  4. Craig Moskowitz (5)
  5. Hans Prochaska (5)
  6. John Gerecitano (5)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2022 (1)
  4. 2019 (1)
  5. 2014 (1)
  6. 2012 (5)

More Years

Publications
  1. British Journal of Haematology (5)
  2. Clinical Cancer Research (5)
  3. Journal of Clinical Oncology (5)
  4. Blood (4)
  5. Current Treatment Options in Oncology (2)
  6. Journal of the National Comprehensive Cancer Network (2)

More Publications

Publishers
  1. American Association for Cancer Research (6)
  2. John Wiley & Sons (6)
  3. American Society of Clinical Oncology (5)
  4. Springer (5)
  5. American Society of Hematology (4)
  6. Elsevier Inc. (3)

More Publishers

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The future of small molecule inhibitors in lymphoma
    Journal Article

    Gerecitano, J.
    Current Oncology Reports (2009)

    Fulltext@MSK | Save
  • A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    Journal Article

    Aghajanian, C.; Blessing, J. A.; Darcy, K. M.; Reid, G.; DeGeest, K.; Rubin, S. C.; Mannel, R. S.; Rotmensch, J.; Schilder, R. J.; Riordan, W.
    Gynecologic Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
    Journal Article

    Rosenberg, J. E.; Halabi, S.; Sanford, B. L.; Himelstein, A. L.; Atkins, J. N.; Hohl, R. J.; Millard, F.; Bajorin, D. F.; Small, E. J.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
    Journal Article

    Paoluzzi, L.; Gonen, M.; Bhagat, G.; Furman, R. R.; Gardner, J. R.; Scotto, L.; Gueorguiev, V. D.; Heaney, M. L.; Manova, K.; O'Connor, O. A.
    Blood (2008)

    Fulltext@MSK | Save
  • Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis
    Journal Article

    Wu, K. D.; Zhou, L.; Burtrum, D.; Ludwig, D. L.; Moore, M. A. S.
    Cancer Immunology, Immunotherapy (2007)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications
    Journal Article

    Kukreja, A.; Hutchinson, A.; Mazumder, A.; Vesole, D.; Angitapalli, R.; Jagannath, S.; O'Connor, O. A.; Dhodapkar, M. V.
    British Journal of Haematology (2007)

    Fulltext@MSK | Save
  • An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
    Journal Article

    Stubblefield, M. D.; Slovin, S.; Macgregor-Cortelli, B.; Muzzy, J.; Scher, H.; Wright, J.; Esseltine, D.; Schenkein, D.; O'Connor, O. A.
    Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas
    Journal Article

    Paoluzzi, L.; O'Connor, O. A.
    BioDrugs (2006)

    Fulltext@MSK | Save
  • The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Journal Article

    O'Connor, O. A.; Smith, E. A.; Toner, L. E.; Teruya-Feldstein, J.; Frankel, S.; Rolfe, M.; Wei, X.; Liu, S.; Marcucci, G.; Chan, K. K.; more...
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save